Healthcare Services

Nontuberculous Mycobacterial Infection Market Analysis Reflecting Expansion Trends And Industry Performance

June 2, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Does The Forecasted Market Size Of The Nontuberculous Mycobacterial Infection Market Compare Between 2026 And 2030?

The nontuberculous mycobacterial infection market has experienced robust expansion in recent years. It is projected to increase from $14.96 billion in 2025 to $15.87 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 6.1%. The historical growth in this market can be attributed to several factors including a high incidence of pulmonary infections, the limited availability of effective therapies, delays in the diagnosis of nontuberculous mycobacteria, a reliance on conventional antibiotic regimens, and low awareness among clinicians.

The nontuberculous mycobacterial infection market is anticipated to experience substantial expansion in the coming years. This market is projected to reach $21.01 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.3%. Factors contributing to this growth during the forecast period include the increasing uptake of macrolide and rifampin combination treatments, enhanced availability of aminoglycosides, the rise of personalized therapeutic methods, the widening reach of hospital and specialty pharmacy networks, and the creation of AI-powered monitoring and diagnostic instruments. Key trends anticipated in the forecast period encompass the growing acceptance of macrolide and rifampin therapies, the expanded application of aminoglycoside-based treatments, the broader adoption of combination drug protocols, the increasing deployment of sophisticated diagnostic tools, and the progressive incorporation of AI-driven treatment surveillance.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13020&type=smp

Which Core Factors Are Supporting The Expansion Of The Nontuberculous Mycobacterial Infection Market?

The expanding occurrence of chronic obstructive pulmonary disease (COPD) is anticipated to drive the development of the nontuberculous mycobacterial infection market. COPD is a persistent respiratory ailment marked by ongoing and often worsening restrictions in lung airflow. For individuals with COPD, nontuberculous mycobacterial (NTM) infections are linked to a more pronounced reduction in forced expiratory volume in one second (FEV1) and a higher rate of exacerbations. This is because COPD can compromise the immune system and harm lung tissue, thereby increasing the susceptibility to NTM bacterial infection. As an illustration, in September 2024, Public Health Scotland, a government health agency based in Scotland, reported that in Scotland during 2022/23, the incidence of COPD, determined by hospital admissions and death records, was 112.4 cases per 100,000 for females and 109.7 cases per 100,000 for males. Consequently, the increasing prevalence of chronic obstructive pulmonary disease (COPD) fuels the expansion of the nontuberculous mycobacterial infection market.

What Key Segment Areas Are Included In The Nontuberculous Mycobacterial Infection Market Assessment?

The nontuberculous mycobacterial infection market covered in this report is segmented –

1) By Drug Class: Macrolides, Rifampin, Aminoglycoside, Other Drug Classes

2) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Macrolides: Azithromycin, Clarithromycin, Erythromycin

2) By Rifampin: Rifampin Monotherapy, Rifampin Combination Therapy, Extended-Duration Rifampin Therapy

3) By Aminoglycoside: Amikacin, Streptomycin, Tobramycin

4) By Other Drug Classes: Fluoroquinolones, Ethambutol, Linezolid, Clofazimine

What Trends Are Influencing The Nontuberculous Mycobacterial Infection Market?

Leading companies in the non-surgical cosmetic procedures market are concentrating on developing technological advancements, such as micro-focused ultrasound skin-lifting platforms, to meet the increasing demand for effective, non-invasive facial rejuvenation, skin tightening, and treatments for age-related skin laxity. A micro-focused ultrasound system delivers precise ultrasound energy to deep dermal and sub-dermal tissue layers, stimulating natural collagen and elastin production without incisions, anesthesia, or downtime, thereby offering a non-surgical alternative to traditional facelifts. For instance, in September 2024, Merz Aesthetics, a U.S.-based medical aesthetics company, launched Ultherapy PRIME, an advanced non-invasive skin-lifting platform. This product provides customizable energy delivery with real-time imaging, enhances collagen stimulation, and delivers visible lifting and firming results in a single session, while minimizing recovery time compared to surgical alternatives.

Who Are The Companies Shaping The Nontuberculous Mycobacterial Infection Market Landscape?

Major companies operating in the nontuberculous mycobacterial infection market are Teva Pharmaceutical Industries Ltd., Mylan N.V., Sun Pharmaceutical Industries Ltd., Lupin Limited, Insmed Incorporated, Paratek Pharmaceuticals Inc., Spero Therapeutics Inc., Aradigm Corporation, Dauntless Pharmaceuticals Inc., Validus Pharmaceuticals LLC, Savara Inc, Mannkind Corporation, Matinas BioPharma Holdings Inc, Vast Therapeutics Inc, Crestone Inc, AN2 Therapeutics Inc, Revimmune Inc, Shionogi Co Ltd, Summit Therapeutics plc, BioVersys AG, RedHill Biopharma Ltd, Shanghai MicuRx Pharmaceutical Co Ltd, Otsuka Pharmaceutical Co Ltd, Cipla Limited, Daiichi Sankyo Company Ltd.

Access The Complete Nontuberculous Mycobacterial Infection Market Report:

https://www.thebusinessresearchcompany.com/report/nontuberculous-mycobacterial-infection-global-market-report

Which Region Stands As The Largest Contributor To The Nontuberculous Mycobacterial Infection Market?

North America was the largest region in the nontuberculous mycobacterial infection market in 2025. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the nontuberculous mycobacterial infection market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Nontuberculous Mycobacterial Infection Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=13020&type=smp

Browse Through More Reports Similar to the Global Nontuberculous Mycobacterial Infection Market 2026, By The Business Research Company

Waterless Cosmetics Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/waterless-cosmetics-global-market-report

Mineral Cosmetics Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/mineral-cosmetics-global-market-report

Vegan Cosmetics Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/vegan-cosmetics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795